MiMedx (NSDQ:MDXG) announced today that its recently filed shelf registration with the SEC has become effective.
Marietta, Georgia-based MiMedx last month filed the shelf registration statement on Form S-3 with the SEC with the intent to be allowed to sell up to $350 million in various types of securities over the next three years once the shelf registration was declared effective.
The company said in a news release that the specifics of any future offering, along with prices and terms of any such securities, plus the use of proceeds in connection with that offering, will be determined at the time of the offering, following the shelf registration being made effective.
MiMedx develops AmnioFix, a micronized dehydrated human amnion/chorion membrane (dHACM) injection as regenerative medicine.
